Zai Lab (ZLAB) to Release Earnings on Thursday

Zai Lab (NASDAQ:ZLAB) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Zai Lab to post earnings of ($0.65) per share and revenue of $110.15 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Zai Lab Stock Performance

Shares of ZLAB stock opened at $33.91 on Wednesday. Zai Lab has a fifty-two week low of $13.48 and a fifty-two week high of $36.60. The firm has a market capitalization of $3.71 billion, a PE ratio of -12.24 and a beta of 1.02. The stock’s 50-day simple moving average is $27.17 and its 200-day simple moving average is $25.57.

Insiders Place Their Bets

In other Zai Lab news, insider Rafael Amado sold 7,583 shares of the stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total transaction of $199,281.24. Following the completion of the transaction, the insider now owns 33,834 shares of the company’s stock, valued at $889,157.52. This represents a 18.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 13.88% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald upgraded Zai Lab to a “strong-buy” rating in a research note on Wednesday, February 5th.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.